NZ732075A - Detection and treatment of excessive hair shedding - Google Patents

Detection and treatment of excessive hair shedding

Info

Publication number
NZ732075A
NZ732075A NZ732075A NZ73207515A NZ732075A NZ 732075 A NZ732075 A NZ 732075A NZ 732075 A NZ732075 A NZ 732075A NZ 73207515 A NZ73207515 A NZ 73207515A NZ 732075 A NZ732075 A NZ 732075A
Authority
NZ
New Zealand
Prior art keywords
hair
range
minoxidil
shedding
oral
Prior art date
Application number
NZ732075A
Other languages
English (en)
Inventor
Rodney Sinclair
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55856287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ732075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904327A external-priority patent/AU2014904327A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of NZ732075A publication Critical patent/NZ732075A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ732075A 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding NZ732075A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014904327A AU2014904327A0 (en) 2014-10-29 Detection and treatment of excessive hair shedding
PCT/AU2015/050682 WO2016065426A1 (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding

Publications (1)

Publication Number Publication Date
NZ732075A true NZ732075A (en) 2022-09-30

Family

ID=55856287

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ732075A NZ732075A (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding

Country Status (11)

Country Link
US (2) US10226462B2 (enExample)
EP (2) EP3626244B1 (enExample)
JP (2) JP6915946B2 (enExample)
KR (2) KR102625061B1 (enExample)
CN (2) CN107106560A (enExample)
AU (4) AU2015337807B2 (enExample)
CA (2) CA3209849A1 (enExample)
ES (2) ES2952159T3 (enExample)
NZ (1) NZ732075A (enExample)
SG (2) SG10202002705YA (enExample)
WO (1) WO2016065426A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102625061B1 (ko) 2014-10-29 2024-01-16 삼손 클리니컬 피티와이 엘티디 과도한 모발 쉐딩의 검출 및 치료
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20180189976A1 (en) 2016-12-29 2018-07-05 Michal Kasprzak Analysis unit and system for assessment of hair condition
WO2019010535A1 (en) * 2017-07-12 2019-01-17 Samson Clinical Pty Ltd STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA
JP7777448B2 (ja) * 2018-09-13 2025-11-28 エイリオン セラピューティクス， インコーポレイテッド プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ－１）阻害剤（ｉｎｈｉｂｉｔｏｒ）の使用
CN109674762A (zh) * 2019-03-05 2019-04-26 南京正大天晴制药有限公司 一种度他雄胺及治疗脱发的组合物胶囊
CN110478450B (zh) * 2019-10-09 2021-04-13 北海鑫臻药业有限公司 一种治疗阿尔茨海默病的药物组合物及其应用
CN111110721A (zh) * 2020-01-19 2020-05-08 朱炜 一种毛发防脱再生的复合制剂及其使用方法
WO2021172060A1 (ja) * 2020-02-27 2021-09-02 パナソニックＩｐマネジメント株式会社 画像処理装置及び画像処理方法
US12622907B2 (en) 2021-09-29 2026-05-12 Nirmana Health, Inc. Hair loss therapy
US11744788B2 (en) * 2021-10-27 2023-09-05 James D. Welch Method of encouraging growth and regrowth of hair in human males technical area
JP2025536556A (ja) * 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
CN119947694A (zh) * 2023-09-01 2025-05-06 芙丽亚国际公司 用于治疗脱发症的口服米诺地尔的口服补充剂的方法和组合物
US20250213594A1 (en) * 2023-12-27 2025-07-03 Inventage Lab Inc. Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1992008705A1 (en) * 1990-11-14 1992-05-29 The Upjohn Company 5-fluoro-2,4,6-pyrimidinetriamine compounds
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
GB2314019B (en) 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
WO1999040898A2 (en) 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
JP2000038340A (ja) 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2003012542A (ja) 2001-06-26 2003-01-15 Toray Ind Inc 発毛促進剤
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CN1838969A (zh) 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
US20080064765A1 (en) * 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
US8110655B2 (en) * 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
EP2344198B1 (en) * 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Lipid based pharmaceutical preparations for topical application
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
KR102625061B1 (ko) 2014-10-29 2024-01-16 삼손 클리니컬 피티와이 엘티디 과도한 모발 쉐딩의 검출 및 치료
US9561224B1 (en) 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia
WO2019010535A1 (en) 2017-07-12 2019-01-17 Samson Clinical Pty Ltd STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Also Published As

Publication number Publication date
US20190192513A1 (en) 2019-06-27
AU2020203695B2 (en) 2021-09-02
CA3003940A1 (en) 2016-05-06
US11116770B2 (en) 2021-09-14
AU2015337807A1 (en) 2017-04-13
ES2952159T3 (es) 2023-10-27
AU2018279055A1 (en) 2019-01-17
AU2020203695A1 (en) 2020-06-25
CN107106560A (zh) 2017-08-29
AU2015337807B2 (en) 2017-05-04
HK1243641A1 (en) 2018-07-20
EP3626244A1 (en) 2020-03-25
EP3626244B1 (en) 2023-06-07
JP2017533265A (ja) 2017-11-09
KR20240011239A (ko) 2024-01-25
AU2017210523A1 (en) 2017-08-17
US20170333432A1 (en) 2017-11-23
AU2017210523B2 (en) 2018-11-15
ES2773467T3 (es) 2020-07-13
JP6915946B2 (ja) 2021-08-11
EP3212192A1 (en) 2017-09-06
EP3212192B1 (en) 2019-11-20
CN115998740A (zh) 2023-04-25
CA3003940C (en) 2023-10-10
CA3209849A1 (en) 2016-05-06
SG11201703424WA (en) 2017-05-30
JP2020109127A (ja) 2020-07-16
KR102625061B1 (ko) 2024-01-16
US10226462B2 (en) 2019-03-12
SG10202002705YA (en) 2020-05-28
WO2016065426A1 (en) 2016-05-06
EP3212192A4 (en) 2018-07-04
KR20170102214A (ko) 2017-09-08

Similar Documents

Publication Publication Date Title
AU2020203695B2 (en) Detection and treatment of excessive hair shedding
Asghar et al. Telogen effluvium: a review of the literature
Moftah et al. Mesotherapy using dutasteride‐containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation
Banka et al. Pattern hair loss in men: diagnosis and medical treatment
Olsen et al. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo
Torres Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management
EP1638582B1 (en) Use of hyaluronic acid for preparing compositions for treating recurrent oral cavity aphthas
Godse et al. Low-dose oral minoxidil in the treatment of alopecia: evidence and experience-based consensus statement of Indian experts
HK40023042A (en) Oral minoxidil for the treatment of alopecia areata
HK40023042B (en) Oral minoxidil for the treatment of alopecia areata
Lubov et al. Central centrifugal cicatricial alopecia in Black men: A case series highlighting key clinical features in this cohort
HK1243641B (en) Oral minoxidil for the treatment of telogen effluvium
Ozlu et al. Telogen effluvium
Katoulis et al. Frontal fibrosing alopecia
Turgut et al. Hair loss due to pregabaline: a case report
Hamzeh et al. Common Causes of Hair Loss
de Oliveira Community Pharmacy and Hospital Pharmacy Internship Reports and Monograph" Counseling for Androgenetic Alopecia-The Pharmacist's Role"
Roberts Geriatric hair and scalp disorders
Carter Interventions for female pattern hair loss
Srilakshmi Clinico-Epidemiological Study of Alopecias in Females in Correlation with Serum Ferritin, Vitamin B12 and Thyroid Profile
Strachan Evaluation of hair loss

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2024 BY FB RICE PTY LTD

Effective date: 20231003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2025 BY FB RICE PTY LTD

Effective date: 20240905

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2026 BY FB RICE PTY LTD

Effective date: 20251008